Cancer-Killing virus shows promise in early trial for advanced tumors

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to standard treatments. MEM-288 is injected directly into accessible tumors, either alone or combined with standard therapies like nivolumab or docetaxel. The main goals are to find the safest dose and check for any early signs of tumor shrinkage.